Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
Luca Malorni(Azienda Usl Toscana Centro), Rachel Schiff(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), Myles Brown(Harvard University), Meghana V. Trivedi(University of Houston), Chad J. Creighton(Baylor College of Medicine), Rinath Jeselsohn(Dana-Farber Cancer Institute), Nuala Healy(St. James's Hospital), Mario Giuliano(Regione Campania), Xiaoyong Fu(King University), Powel H. Brown(The University of Texas MD Anderson Cancer Center), Susan G. Hilsenbeck(Baylor College of Medicine), Sabino De Placido, Abhijit Mazumdar(The University of Texas MD Anderson Cancer Center), Ilenia Migliaccio(Hospital of Prato), Tao Wang(Pfizer (United States)), C. Kent Osborne(Baylor College of Medicine), Mathieu Lupien(Ontario Institute for Cancer Research), Suleiman Massarweh(University of Kentucky), Carolina Gutiérrez(Baylor College of Medicine)
Cited by 0
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k